-+ 0.00%
-+ 0.00%
-+ 0.00%
Palatin Technologies Presents New Preclinical Data Highlighting Its Proprietary MC4R-Selective Peptide Agonist Programs At ObesityWeek 2026
Share
Listen to the news
  • Novel peptide and long-acting lipidated peptide agonists demonstrate potent MC4R activity with minimal to no MC1R activity, supporting the potential to substantially reduce or eliminate hyperpigmentation
     
  • Significant reductions in body weight and food intake demonstrated in preclinical models, with encouraging preliminary cardiovascular finding
     
  • Proprietary lipidation technology supports once-weekly or potentially less frequent dosing; lead candidate PL2001 advancing toward first-in-human studies in the first half of 2027

PRINCETON, N.J., Nov. 16, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NASDAQ:PTN), a biopharmaceutical company developing differentiated, next-generation melanocortin receptor agonists, today announced the presentation of new preclinical data highlighting the Company's proprietary MC4R-selective peptide agonist programs at ObesityWeek® 2026, being held November 14–17 in Washington, D.C.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending